RxDoctor Payments Data

Allison Young, MD

Ophthalmology · San Antonio, TXNPI 1750501029

Payments from drug & device makers

$7,725in general payments, 2019–2025

Across 197 payments — averaging $39.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • Biotissue Holdings Inc.$1K
  • AbbVie$1K
  • Rxsight Inc$508
  • Sun Pharmaceutical Industries Inc.$482
  • Amgen$439
  • plus $3K from 19 others

What the payments were for

  • Speaking & faculty fees$260%
  • Food & beverage$7,700100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,725 in reported general payments places this provider in the 75th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$512,542
Medicare patients
1,458
Services billed
3,779

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine101$135,479
XiidraLifitegrast40$63,661
Cyclosporine61$39,619
LumiganBimatoprost60$36,588
MieboPerfluorohexyloctane/Pf41$32,874
CequaCyclosporine14$18,461
VevyeCyclosporine20$17,678
RocklatanNetarsudil Mesylat/Latanoprost23$15,247
VyzultaLatanoprostene Bunod15$9,714
Travoprost30$9,488
ProlensaBromfenac Sodium26$8,790
Prednisolone Acetate158$5,411
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol21$4,935
MoxifloxacinMoxifloxacin Hcl223$3,475
Bromfenac Sodium19$2,884

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$1,057$172,066161 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta$402$106,25096 claims
Sun Pharmaceutical Industries Inc.Cequa$482$18,46114 claims
Harrow Eye, LLCVevye$347$17,67820 claims
Aerie Pharmaceuticals, Inc.Rocklatan$252$15,24723 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$112$8,79026 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →